Experience with sorafenib and adverse event management.

  title={Experience with sorafenib and adverse event management.},
  author={Joaquim Bellmunt and Timothy J Eisen and Mayer Fishman and David Quinn},
  journal={Critical reviews in oncology/hematology},
  volume={78 1},
Sorafenib was the first multikinase inhibitor to be approved for use in renal cell cancer (RCC) in the US (2005) and in Europe (2006). In the Treatment Approaches in Renal Cell Cancer Global Evaluation Trial (TARGET), sorafenib showed a significant progression-free survival advantage over placebo in patients with advanced RCC. Incidence rates of adverse events were significantly higher with sorafenib than with placebo. Management of adverse events is an essential component of care to prevent… CONTINUE READING
27 Citations
36 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 27 extracted citations


Publications referenced by this paper.
Showing 1-10 of 36 references

A large open - label , noncomparative , phase III study of the multitargeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma

  • J Beck, B Escudier, E Verzoni
  • Cancer
  • 2010

Similar Papers

Loading similar papers…